JP2020521456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521456A5 JP2020521456A5 JP2019564937A JP2019564937A JP2020521456A5 JP 2020521456 A5 JP2020521456 A5 JP 2020521456A5 JP 2019564937 A JP2019564937 A JP 2019564937A JP 2019564937 A JP2019564937 A JP 2019564937A JP 2020521456 A5 JP2020521456 A5 JP 2020521456A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- polypeptide
- seq
- active fragment
- biologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022166786A JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A JP2024055980A (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511194P | 2017-05-25 | 2017-05-25 | |
| US62/511,194 | 2017-05-25 | ||
| US201762567417P | 2017-10-03 | 2017-10-03 | |
| US62/567,417 | 2017-10-03 | ||
| PCT/US2018/034726 WO2018218194A1 (en) | 2017-05-25 | 2018-05-25 | Cblb endonuclease variants, compositions, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166786A Division JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521456A JP2020521456A (ja) | 2020-07-27 |
| JP2020521456A5 true JP2020521456A5 (enExample) | 2021-05-20 |
| JP7191042B2 JP7191042B2 (ja) | 2022-12-16 |
Family
ID=64395994
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564937A Active JP7191042B2 (ja) | 2017-05-25 | 2018-05-25 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2022166786A Active JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A Pending JP2024055980A (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166786A Active JP7450683B2 (ja) | 2017-05-25 | 2022-10-18 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
| JP2024032998A Pending JP2024055980A (ja) | 2017-05-25 | 2024-03-05 | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US12227740B2 (enExample) |
| EP (1) | EP3630962A4 (enExample) |
| JP (3) | JP7191042B2 (enExample) |
| KR (2) | KR102590466B1 (enExample) |
| CN (1) | CN110799644A (enExample) |
| AU (2) | AU2018273979B2 (enExample) |
| CA (1) | CA3064014A1 (enExample) |
| IL (2) | IL270776B2 (enExample) |
| MA (1) | MA48797A (enExample) |
| MX (1) | MX2019014100A (enExample) |
| NZ (1) | NZ759382A (enExample) |
| WO (1) | WO2018218194A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
| AU2018273979B2 (en) | 2017-05-25 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | CBLB endonuclease variants, compositions, and methods of use |
| EP4365194A3 (en) | 2018-06-14 | 2024-07-24 | Regeneron Pharmaceuticals, Inc. | Cd79a chimeric antigen receptors |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
| WO2020123375A1 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Pdcd-1 homing endonuclease variants |
| CA3122278A1 (en) | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
| US20240034768A1 (en) * | 2018-12-14 | 2024-02-01 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| BR112021025259A2 (pt) * | 2019-06-14 | 2022-03-15 | 2Seventy Bio Inc | Composições e métodos para tratar câncer |
| HRP20251116T1 (hr) | 2020-07-20 | 2025-11-21 | Enanta Pharmaceuticals, Inc. | Funkcionalizirani peptidi koji sadrže dva pirolidinska prstena kao antikoronavirusni agensi |
| US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| EP4247387A1 (en) | 2020-11-23 | 2023-09-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CA3202889A1 (en) * | 2020-12-21 | 2022-06-30 | Jordan JARJOUR | Compositions and methods for site-directed mutagenesis |
| US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| AU6972301A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Duplexed parvovirus vectors |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| WO2009059195A2 (en) | 2007-10-31 | 2009-05-07 | Precision Biosciences | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US20110294217A1 (en) | 2009-02-12 | 2011-12-01 | Fred Hutchinson Cancer Research Center | Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion |
| CN105384827A (zh) | 2009-11-27 | 2016-03-09 | 巴斯夫植物科学有限公司 | 嵌合内切核酸酶及其用途 |
| EP2524037B1 (en) | 2010-01-12 | 2018-05-16 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| ES2628889T3 (es) | 2010-02-05 | 2017-08-04 | The University Of North Carolina At Chapel Hill | Composiciones y métodos para la transducción mejorada del parvovirus |
| US20140148361A1 (en) | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
| SG189482A1 (en) | 2010-10-27 | 2013-05-31 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| ES2906059T3 (es) | 2011-02-28 | 2022-04-13 | Seattle Childrens Res Institute | Endonucleasas de acoplamiento con enzimas de procesamiento de extremos que impulsan la interrupción génica de alta eficiencia |
| CA3111953C (en) * | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| US9758796B2 (en) | 2011-06-10 | 2017-09-12 | Basf Plant Science Company Gmbh | Nuclease fusion protein and uses thereof |
| US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| WO2014191527A1 (en) | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof |
| WO2014191525A1 (en) * | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
| KR102827558B1 (ko) | 2014-04-18 | 2025-07-11 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4043556B1 (en) | 2015-06-30 | 2024-02-07 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| CN109689865A (zh) | 2016-07-25 | 2019-04-26 | 蓝鸟生物公司 | Bcl11a归巢核酸内切酶变体、组合物和使用方法 |
| US20190309274A1 (en) | 2016-08-16 | 2019-10-10 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
| AU2018273979B2 (en) | 2017-05-25 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | CBLB endonuclease variants, compositions, and methods of use |
| WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
-
2018
- 2018-05-25 AU AU2018273979A patent/AU2018273979B2/en not_active Expired - Fee Related
- 2018-05-25 KR KR1020197036681A patent/KR102590466B1/ko active Active
- 2018-05-25 WO PCT/US2018/034726 patent/WO2018218194A1/en not_active Ceased
- 2018-05-25 IL IL270776A patent/IL270776B2/en unknown
- 2018-05-25 KR KR1020237034961A patent/KR102742817B1/ko active Active
- 2018-05-25 JP JP2019564937A patent/JP7191042B2/ja active Active
- 2018-05-25 US US16/616,713 patent/US12227740B2/en active Active
- 2018-05-25 EP EP18806825.8A patent/EP3630962A4/en active Pending
- 2018-05-25 NZ NZ759382A patent/NZ759382A/en unknown
- 2018-05-25 IL IL313037A patent/IL313037A/en unknown
- 2018-05-25 CN CN201880042211.8A patent/CN110799644A/zh active Pending
- 2018-05-25 MX MX2019014100A patent/MX2019014100A/es unknown
- 2018-05-25 MA MA048797A patent/MA48797A/fr unknown
- 2018-05-25 CA CA3064014A patent/CA3064014A1/en active Pending
-
2019
- 2019-11-25 US US16/694,815 patent/US10927367B2/en active Active
-
2021
- 2021-01-15 US US17/150,293 patent/US11732255B2/en active Active
-
2022
- 2022-10-18 JP JP2022166786A patent/JP7450683B2/ja active Active
-
2024
- 2024-03-05 JP JP2024032998A patent/JP2024055980A/ja active Pending
-
2025
- 2025-01-16 AU AU2025200323A patent/AU2025200323A1/en active Pending
- 2025-02-13 US US19/052,367 patent/US20250179469A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521456A5 (enExample) | ||
| JP2019526268A5 (enExample) | ||
| JP2019535240A5 (enExample) | ||
| JP2020507342A5 (enExample) | ||
| JP6748105B2 (ja) | がん治療のための遺伝子改変ｎｋ−９２細胞およびモノクローナル抗体 | |
| JP7191042B2 (ja) | Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法 | |
| US20210309713A1 (en) | Chimeric Antigen Receptor and Method for Treating Cancers | |
| Stärck et al. | Immunotherapy with TCR-redirected T cells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell–derived T cells | |
| KR20160105882A (ko) | 신규한 합성 생물학에 기반한 adcc 기술 | |
| CN113412276A (zh) | 二聚化剂调节的免疫受体复合物 | |
| KR20200110326A (ko) | Daric 인터류킨 수용체 | |
| KR20220031554A (ko) | Cd33 표적화 면역요법 | |
| AU2022312508A1 (en) | Polycistronic vectors for cell-based therapies | |
| CN111655720A (zh) | Nkg2d daric受体 | |
| KR20220031549A (ko) | Cll-1 표적화 면역요법 | |
| CN117529505A (zh) | 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途 | |
| JPWO2022216915A5 (enExample) | ||
| Plougastel et al. | Sequence Analysis of a 62-kb Region Overlapping the HumanKLRCCluster of Genes | |
| Kawazu et al. | Functional domains of Runx1 are differentially required for CD4 repression, TCRβ expression, and CD4/8 double-negative to CD4/8 double-positive transition in thymocyte development | |
| AU2020212683B2 (en) | Cell-specific transcriptional regulatory sequences and uses thereof | |
| CN114402079A (zh) | Cd123靶向免疫疗法 | |
| US6790614B1 (en) | Selectable cell surface marker genes | |
| CN116802203A (zh) | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 | |
| RU2019110065A (ru) | Варианты, композиции и методы применения хоминг-эндонуклеазы pd-1 | |
| AU779462B2 (en) | Selectable cell surface marker genes |